EXACT Therapeutics AS: Primary insider notification

11 December 2024: Reference is made to the primary insider notification published on 3 December 2024 by EXACT Therapeutics AS ("EXACT-Tx" or the "Company") regarding the share lending agreement entered into with, among others, Investinor Direkte AS, PAACS Invest AS and Helene Sundt AS, which are close associates of primary insiders, pursuant to which they granted Carnegie AS an option to borrow ordinary shares to facilitate settlement in the Company's private placement. The new shares have today been registered in the Norwegian Register of Business Enterprises and Carnegie AS has re-delivered the shares to, among others, Investinor Direkte AS, PAACS Invest AS and Helene Sundt AS. Please see the attached notification form for further information. This information is subject to the disclosure requirements in section 5-12 of the Norwegian Securities Trading Act. For more information, please contact: Per Walday, CEO EXACT Therapeutics Email per.walday@exact-tx.com About EXACT-Tx: EXACT-Tx is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com